These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28904393)

  • 1. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
    Awan FM; Naz A; Obaid A; Ikram A; Ali A; Ahmad J; Naveed AK; Janjua HA
    Sci Rep; 2017 Sep; 7(1):11448. PubMed ID: 28904393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma.
    Zhang Z; Tan X; Luo J; Yao H; Si Z; Tong JS
    Cell Death Dis; 2020 Oct; 11(10):902. PubMed ID: 33097691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
    Wang S; Liu D; Wei H; Hua Y; Shi G; Qiao J
    Bioengineered; 2022 Feb; 13(2):2272-2284. PubMed ID: 35034536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
    Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
    Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
    J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
    J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
    Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
    Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
    Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
    Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
    Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
    J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
    Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
    Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR.
    Ji L; Lin Z; Wan Z; Xia S; Jiang S; Cen D; Cai L; Xu J; Cai X
    Cell Death Dis; 2020 Apr; 11(4):250. PubMed ID: 32313144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-30e-3p Influences Tumor Phenotype through
    Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
    Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma.
    Wei L; Wang X; Lv L; Liu J; Xing H; Song Y; Xie M; Lei T; Zhang N; Yang M
    Mol Cancer; 2019 Oct; 18(1):147. PubMed ID: 31651347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression.
    Azumi J; Tsubota T; Sakabe T; Shiota G
    Cancer Sci; 2016 Sep; 107(9):1256-62. PubMed ID: 27384977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p.
    Song W; Zheng C; Liu M; Xu Y; Qian Y; Zhang Z; Su H; Li X; Wu H; Gong P; Li Y; Fan H
    Mol Ther; 2021 Aug; 29(8):2601-2616. PubMed ID: 33839325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence.
    Ruan Y; Chen T; Zheng L; Cai J; Zhao H; Wang Y; Tao L; Xu J; Ji L; Cai X
    Int J Biol Sci; 2023; 19(14):4608-4626. PubMed ID: 37781045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.